inking fecal microbiota composition to anti-saccharomyces cerevisiae antibody (ASCA) production in inflammatory bowel disease (IBD)patients.
Recruiting
- Conditions
- intestinal inflammation10017969
- Registration Number
- NL-OMON44343
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
For all groups:
- Age from 18 years, either male or female
- Ability to give informed consent
- No use of antibiotics or antifungals 3 months prior to sample collection. ;Group specific inclusion criteria:
- Group 1 and 2 the patients have been diagnosed with CD.
- Group 3 patients have been diagnosed with UC patients.
- Group 4 People have not been diagnosed with IBD.
Exclusion Criteria
Inability to give informed consent
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>1) A correlation in CD patiënts between C.albicans strains and ASCA titer in<br /><br>blood.<br /><br>2) A correlation in CD patiënts between fecal microbial composition and ASCA<br /><br>titer in blood.</p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary study parameters are based on a correlation between disease<br /><br>severity (measured by determination of fecal calprotectin) and fecal microbial<br /><br>composition/ fecal C.albicans strains in CD, UC and healthy volunteers.</p><br>